Nanomedicine Market Healthy Pace throughout the Forecast by 2023 – Crypto News Byte

Posted on by

Overview:

Nanomedicine is an offshoot of nanotechnology, and refers to highly-specific medical intervention at the molecular scale for curing diseases or repairing damaged tissues. Nanomedicine uses nano-sized tools for the diagnosis, prevention and treatment of disease, and to gain increased understanding of the complex underlying pathophysiology of the disease. It involves three nanotechnology areas of diagnosis, imaging agents, and drug delivery with nanoparticles in the 11,000 nm range, biochips, and polymer therapeutics.

Get Sample Copy Of The Report@ https://www.trendsmarketresearch.com/report/sample/9807

Majority of nanomedicines prescribedcurrently, allow oral drug delivery and its demand is increasing significantly. Although these nanovectors are designed to translocate across the gastrointestinal tract, lung, and bloodbrain barrier, the amount of drug transferred to the organ is lower than 1%; therefore improvements are challenging. Nanomedicines are designed to maximize the benefit/risk ratio, and their toxicity must be evaluated not only by sufficiently long term in vitro and in vivo studies, but also pass multiple clinical studies.

Market Analysis:

The Global Nanomedicine Market is estimated to witness a CAGR of 17.1% during the forecast period 20172023. The nanomedicine market is analyzed based on two segments therapeutic applications and regions.

The major drivers of the nanomedicine market include its application in various therapeutic areas, increasing R&D studies about nanorobots in this segment, and significant investments in clinical trials by the government as well as private sector. The Oncology segment is the major therapeutic area for nanomedicine application, which comprised more than 35% of the total market share in 2016. A major focus in this segment is expected to drive the growth of the nanomedicine market in the future.

Regional Analysis:

The regions covered in the report are the Americas, Europe, Asia Pacific, and Rest of the World (ROW). The Americas is set to be the leading region for the nanomedicine market growth followed by Europe. The Asia Pacific and ROW are set to be the emerging regions. Japan is set to be the most attractive destination and in Africa, the popularity and the usage of various nano-drugs are expected to increase in the coming years. The major countries covered in this report are the US, Germany, Japan, and Others.

Therapeutic Application Analysis:

Nanomedicines are used as fluorescent markers for diagnostic and screening purposes. Moreover, nanomedicines are introducing new therapeutic opportunities for a large number of agents that cannot be used effectively as conventional oral formulations due to poor bioavailability. The therapeutic areas for nanomedicine application are Oncology, Cardiovascular, Neurology, Anti-inflammatory, Anti-infectives, and various other areas. Globally, the industry players are focusing significantly on R&D to gain approval for various clinical trials for future nano-drugs to be commercially available in the market. The FDA should be relatively prepared for some of the earliest and most basic applications of nanomedicine in areas such as gene therapy and tissue engineering. The more advanced applications of nanomedicine will pose unique challenges in terms of classification and maintenance of scientific expertise.

Request For Report Discount@ https://www.trendsmarketresearch.com/report/discount/9807

Key Players:

Merck & Co. Inc., Hoffmann-La Roche Ltd., Gilead Sciences Inc., Novartis AG, Amgen Inc., Pfizer Inc., Eli Lilly and Company, Sanofi, Nanobiotix SA, UCB SA and other predominate & niche players.

Competitive Analysis:

At present, the nanomedicine market is at a nascent stage but, a lot of new players are entering the market as it holds huge business opportunities. Especially, big players along with the collaboration with other SMBs for clinical trials of nanoparticles and compounds are coming with new commercial targeted drugs in the market and they are expecting a double-digit growth in the upcoming years. Significant investments in R&D in this market are expected to increase and collaborations, merger & acquisition activities are expected to continue.

Benefits:

The report provides complete details about the usage and adoption rate of nanomedicines in various therapeutic verticals and regions. With that, key stakeholders can know about the major trends, drivers, investments, vertical players initiatives, government initiatives towards the nanomedicine adoption in the upcoming years along with the details of commercial drugs available in the market. Moreover, the report provides details about the major challenges that are going to impact on the market growth. Additionally, the report gives the complete details about the key business opportunities to key stakeholders to expand their business and capture the revenue in the specific verticals to analyze before investing or expanding the business in this market.

Report Analysis@ https://www.trendsmarketresearch.com/report/analysis/IR/nanomedicine-market

View more :Healthcare, Pharmaceuticals, & Medical Devices Report Insights

See the rest here:
Nanomedicine Market Healthy Pace throughout the Forecast by 2023 - Crypto News Byte

World Pancreatic Cancer Day: increasing awareness and inspiring action – UNSW Newsroom

Posted on by

Pancreatic cancer is an insidious disease itis often diagnosedat an advanced stage, with about 90% of patients dying within five years of diagnosis.New projections suggest pancreatic cancer will be the second leading cause of cancer mortality by 2025.

This World Pancreatic Cancer Day, we are celebrating some of the many UNSWresearchers who are dedicated to changing those statistics. Cancers with poor outcomes like pancreatic cancer are a key focus area in UNSW Medicine's cancer theme.

Associate Professor Phillips is the Head of the Pancreatic Cancer Translational Research Group and Deputy Director of the Adult Cancer Program at the Lowy Cancer Research Centre at UNSW Medicine.

This year, A/Prof Phillips was a key driver in establishing the Pancreatic Cancer Research Hub, which aims to double the survival of patients with pancreatic cancer by 2030.

She says World Pancreatic Cancer Day is a powerful advocacy event to increase community and government awareness of pancreatic cancer.

It is also a time to reflect on the progress we have made in understanding this terrible disease and focus on the next steps to overcome current clinical challenges to ensure our research efforts bridge the gap and, as in other cancers, improve the outcomes for our patients with pancreatic cancer.

I know that we are on the brink of overturning the unacceptable statistics. Uniting researchers with the community who, unlike in other cancers, dont often get to be a strong voice advocating for themselves and Government will ensure Australian researchers continue to make positive change for pancreatic cancer patients globally.

A/Prof Phillips group has developed a novel cutting-edge way to keep pieces of human pancreatic tumours alive in the laboratory for two weeks after surgical resection.

Our capacity to grow human tumour tissue in the laboratory provides a valuable new clinical tool to test how a patients tumour responds to different chemotherapies and has the potential to immediately inform patient treatment options. Our unique tumour model is superior to other models because it is human in origin and it contains the complex tumour environment present in patients.

In 2016 A/Prof Phillips had a major breakthrough, successfully developing a novel nanomedicine a tiny drug delivery vehicle consisting of a state-of-the-art nanoparticle that can package gene therapy to inhibit any tumour-promoting gene in pancreatic cancer.

With the generous support from the Brian O'Neill Pancreatic Cancer Fundraising Dinner held last night the team will be able to perform essential preclinical studies to test the therapeutic potential of their nano-gene therapy in combination with a clinically approved drug. They also plan on using their expertise to improve the bioavailability of the clinically approved drugs using a nanomedicine approach.

Professor Minoti Apte was the first in the world to isolate and characterise pancreatic stellate cells, a cell type that is now known to play a major role in the progression of both chronic pancreatitis and pancreatic cancer. Coming up with ways to target these cells to prevent them from doing harm is now a major focus of her teams research.

The group has now shown that interrupting the cross-talk between cancer cells and surrounding cells in the microenvironment by targeting a certain signalling pathway reduces tumour growth and eliminates metastasis in early as well as advanced pre-clinical models of pancreatic cancer.

We have also shown that targeting this pathway reduces the risk of recurrence and progression after surgical resection of pancreatic cancer in a mouse model, and are currently working on possible pathways to take our laboratory findings to the clinic, Professor Apte says.

To me, World Pancreatic Cancer Day is a great opportunity to raise awareness in the community about this deadly cancer, but it is also a day to admire the courage and resilience of patients and their carers. These are the people that spur us researchers on to continue working hard to develop new therapeutic approaches to improve outcomes.

Last year, Professor Apte received the Gastroenterological Society of Australia (GESA) Distinguished Researcher Prize 2018. In 2014 she was awarded the Medal of the Order of Australia (OAM), after being named the NSW Woman of the Year in 2015. She was also the 2016 recipient of the Professor Rob Sutherland AO Make a Difference Award at the NSW Premiers Awards for Outstanding Cancer Research an award that recognises highly successful research that is actively changing cancer treatment and improving patient survival.

Dr Angelica Merlot, who is based at the Childrens Cancer Institute, focuses her research on developing new anti-cancer drugs that target drug resistance and suppress cancer spread.

This year, the cancer researcher has won the 2019 NSW Young Woman of the Year award for her achievements and research into treatments for pancreatic and brain cancer. She also won a 2019 Young Tall Poppy Science Award and the 2019 NSW Early Career Researcher of the Year (Biological Sciences) at the NSW Premiers Prizes for Science & Engineering.

Dr Merlot says today is an important day to raise awareness about one of the world's toughest cancers.

This is crucial as it broadens community knowledge, inspires action and supports further research funding for this cancer. It's also a time to remember those whom we have lost and those currently fighting this disease, she says.

Although we've seen a small improvement in the current survival rate, a lot of progress is still required. Further translational research means that there is a greater likelihood that the survival rates can be increased and the journey and treatment of those affected by the cancer can be improved.

Dr Merlot became focused on cancer research as an undergraduate. Her interest in aggressive cancers, such as pancreatic and brain cancer, was motivated by lack of improvement in survival rates over the past decades, largely due to late diagnosis, a lack of screening programs, low awareness of symptoms and a lack of treatment options.

After moving to UNSW Medicine as a Scientia Fellow in 2018, Dr Merlot focused on understanding the mechanisms by which cancer cells grow and adapt to their environment, why drugs become less effective and the development of nanoparticles to improve drug delivery.

Dr Merlots current projects are investigating part of a human cell called the endoplasmic reticulum (ER). The ER is a type of organelle, or subunit within a cell, that has been shown to help cancers grow, spread and develop drug resistance.

Dr Ying Zhu will lead a team of researchers from UNSW to discover much needed early detection methods for pancreatic cancer patients: the UNSW Medicine researcher today received $100,000 grant from the Avner Pancreatic Cancer Foundation. A/Prof Phillips is a co-investigator on this grant.

As current approaches to this research are time and labour intensive, the team will develop an integrated and small device based on nanotechnology for rapid and sensitive exosome analysis. The team will define a set of biomarkers that can differentiate between cancer and non-cancer subjects from cells and plasma carrying early signs of human pancreatic cancer. This novel technology will also be applicable for doctors monitoring the development and customising the treatment of a patients tumour.

Pancreatic cancer is difficult to diagnose in the early stages. Early tumour cant be observed during routine physical exams as the pancreas is deep inside the body. Most patients are diagnosed when the cancer has become very large or has spread to other organs. A method to detect pancreatic cancer early on is urgently needed, Dr Zhu said.

My project team aims to develop a blood test to detect pancreatic cancer in the early stages. The team will target exosomes, which are nanosized fragments released by cancer cells. Exosomes are important for communicating messages and transporting materials between cells. Exosomes have been identified as more accurate and promising biomarkers, or biological clues for pancreatic cancer diagnosis, Dr Zhu continued.

We are pleased to award funding to this innovative project, said Michelle Stewart, CEO of the Avner Pancreatic Cancer Foundation. We are encouraged by the high calibre of the research and believe that investment into projects like these will help us to increase survival for people diagnosed with pancreatic cancer.

Read more here:
World Pancreatic Cancer Day: increasing awareness and inspiring action - UNSW Newsroom

Bradley Nelson : Medical MicroRobotics and NanoMedicine : Teruko Yata Memorial Lecture in Robotics – Video

Posted on by


Bradley Nelson : Medical MicroRobotics and NanoMedicine : Teruko Yata Memorial Lecture in Robotics
Brad Nelson ETH Zrich April 16, 2015 While the futuristic vision of micro and nanorobotics is of intelligent machines that navigate throughout our bodies searching for and destroying disease,...

By: cmurobotics

See the original post here:
Bradley Nelson : Medical MicroRobotics and NanoMedicine : Teruko Yata Memorial Lecture in Robotics - Video

Journal of Nanomedicine & Biotherapeutic Discovery

Posted on by

Nanomedicine is an application of nanotechnology which made its debut with greatly increased possibilities in the field of medicine. Nanomedicine desires to deliver research tools and clinically reformative devices in the near future.

Journal of Nanomedicine & Biotherapeutic Discovery is a scholarly open access journal publishing articles amalgamating broad range of fields of novel nano-medicine field with life sciences. Nanomedicine & Biotherapeutic Discovery is an international, peer-reviewed journal providing an opportunity to researchers and scientist to explore the advanced and latest research developments in the field of nanoscience & nanotechnology.

This is the best academic journal which focuses on the use nanotechnology in diagnostics and therapeutics; pharmacodynamics and pharmacokinetics of nanomedicine, drug delivery systems throughout the biomedical field, biotherapies used in diseases treatment including immune system-targeted therapies, hormonal therapies to the most advanced gene therapy and DNA repair enzyme inhibitor therapy. The journal also includes the nanoparticles, bioavailability, biodistribution of nanomedicines; delivery; imaging; diagnostics; improved therapeutics; innovative biomaterials; regenerative medicine; public health; toxicology; point of care monitoring; nutrition; nanomedical devices; prosthetics; biomimetics and bioinformatics.

The journal includes a wide range of fields in its discipline to create a platform for the authors to make their contribution towards the journal and the editorial office promises a peer review process for the submitted manuscripts for the quality of publishing. Biotherapeutics journals impact factors is mainly calculated based on the number of articles that undergo single blind peer review process by competent Editorial Board so as to ensure excellence, essence of the work and number of citations received for the same published articles.

The journal is using Editorial Manager System for quality peer review process. Editorial Manager is an online manuscript submission, review and tracking systems. Review processing is performed by the editorial board members of Journal of Nanomedicine & Biotherapeutic Discovery or outside experts; at least two independent reviewers approval followed by editor approval is required for acceptance of any citable manuscript. Authors may submit manuscripts and track their progress through the system, hopefully to publication. Reviewers can download manuscripts and submit their opinions to the editor. Editors can manage the whole submission/review/revise/publish process.

Submit manuscript at http://editorialmanager.com/chemistryjournals/ or send as an e-mail attachment to the Editorial Office atnanomedicine@molecularbiologyjournals.com

OMICS International through its Open Access Initiative is committed to make genuine and reliable contributions to the scientific community. OMICS International hosts over 700 leading-edge peer reviewed Open Access Journals and organizes over 1000 International Conferences annually all over the world. OMICS International journals have over 10 million readers and the fame and success of the same can be attributed to the strong editorial board which contains over 50000 eminent personalities that ensure a rapid, quality and quick review process. OMICS International signed agreements with more than 1000 International Societies to make healthcare information Open Access. OMICS International Conferences make the perfect platform for global networking as it brings together renowned speakers and scientists across the globe to a most exciting and memorable scientific event filled with much enlightening interactive sessions, world class exhibitions and poster presentations.

Antibody Drug Conjugates (ADC) is also called as smart bombs which are designed to target the cancer cells without disturbing the healthy cells. Nanotherapeutics, Lipid Nanoparticle siRNA Deliverey, Polymeric Nanoparticles, is used in the development of Antibody Drug Conjugates.

Related Journals of Antibodies Drug Conjugates

NanomedicineJournal, InternationalJournal of Nanomedicine, Journal of Nanomaterials & Molecular Nanotechnology, Artificial Cells,Nanomedicineand Biotechnology, Journal of Nanomedicine and Nanotechnology, European Journal ofNanomedicine, OpenNanomedicineJournal, NatureNanotechnology, Nanotechnology, Journal of Nanoscience and Nanotechnology

Nanomedicine is the application of nanotechnology (the engineering of tiny machines) to the prevention and treatment of disease in the human body. This evolving discipline has the potential to dramatically change medical science. Nanobiotechnology is the application of nanotechnology in biological fields. Nanotechnology is a multidisciplinary field that currently recruits approach, technology and facility available in conventional as well as advanced avenues of engineering, physics, chemistry and biology. Nanobiotechnology is like to be advantageous as: 1. Drug targeting can be achieved by taking advantage of the distinct pathophysiological features of diseased tissues 2. Various nanoproducts can be accumulated at higher concentrations than normal. Related Journals of Nanomedicine and Nanobiotechnology Nanomedicine:Nanotechnology, Biologyand Medicine, Journal of International Journal of Nanomedicine, Journal of Nanomedicine Research, Nanomedicine Journal, Nanomedicine Biotherapeutics Journals, European Journal of Nanomedicine

Nanomedicine is the application of nanotechnology (the engineering of tiny machines) to the prevention and treatment of disease in the human body. This evolving discipline has the potential to dramatically change medical science. Nanomedicine will employ molecular machine systems to address medical problems, and will use molecular knowledge to maintain and improve human health at the molecular scale. Nanomedicine will have extraordinary and far-reaching implications for the medical profession, for the definition of disease, for the diagnosis and treatment of medical conditions including aging, and ultimately for the improvement and extension of natural human biological structure and function. "Nanomedicine is the preservation and improvement of human health using molecular tools and molecular knowledge of the human body." Related Journals of Nanomedicine InternationalJournal of Nanomedicine, EuropeanJournal of Nanomedicine Nanomedicine, NanomedicineNanotechnology Journals, Journal of International Journal of Nanomedicine, Journal of Nanomedicine Research, Nanomedicine Journal, Nanomedicine Biotherapeutics Journals, European Journal of Nanomedicine

Nanotechnology is the branch of technology that deals with dimensions and tolerances of less than 100 nanometres, especially the manipulation of individual atoms and molecules. 'Nanotechnology' refers to the projected ability to construct items from the bottom up, using techniques and tools being developed today to make complete, high performance products. Nanotechnology is helping to considerably improve, even revolutionize, many technology and industry sectors: information technology, energy , environmental science, medicine, homeland security, food safety, and transportation, among many others. Related Journals of Nanotechnology

JournalJournal of Interdisciplinary Nanomedicine, Journalof Nanomedicine Research, International Journal of Green Nanotechnology, Beilstein Journal of Nanotechnology, Journal of Nanotechnology, Science and Applications, American Journal of Nanotechnology, Journal of Nano Research

Biotherapeutics are the essential tools of modern therapies derived from living organisms. The living organisms or the cells are modified such that they produce proteins that treat diseases and help to improve health. These help in preventing serious disease and illnesses, such as rheumatoid arthritis, multiple sclerosis and cancer.

Related Journals of Clinical Biotherapeutics

JSMNanotechnology & Nanomedicine, InternationalJournal of Nanomaterials, Journal of Genetic Syndromes & Gene Therapy, Clinical Therapeutics, Journal of Clinical Pharmacy and Therapeutics, Journal of Nanoscience and Nanotechnology, Nanomedicine:Nanotechnology, Biology, and Medicine, IEEE Transactions onNanotechnology, Journal of BiomedicalNanotechnology, International Journal ofNanotechnology, Beilstein Journal ofNanotechnology

Many approaches have been applied in preclinical and clinical strategies to overcome cancer for example chemosensitizers and nanomedicine. Nanomedicine is used as delivery vehicles that increase the influx of the drugs into the cancer cells. Carbon nanotubes are also a very important in the field of medicine due to its property of drug delivery systems and diagnostics. Experts in the field of nanomedicine say that there are wide ranges of uses of this field in the discovery of spherical nucleic acid nanoparticles, nanoscale engineering behind organs-on-a chip, precision medicine.

Related Journals of Experts Opinion on Nanomedicine

Nanotechnologyand Nanomedicine, InternationalJournal of Nanomedicine and Nanosurgery, Journalof Nanomedicine & Nanotechnology, International Journal ofGreen Nanotechnology, RSC Nanoscience and Nanotechnology, OpenNanomedicine Journal, Nanomaterials andNanotechnology,NanotechnologyPerceptions, NanoscienceandNanotechnology- Asia, International Journal ofGreenNanotechnology, RSC Nanoscience andNanotechnology

Nanobiotechnology has a great impact on the health issues of humans, as nanoparticles and nanomaterials have provided targeted drug delivery system. Thus, providing human race to fight against diseases such as cancer, diabetes, to combat antimicrobial resistance, and many more. Coming to the implications of this technology has few backdrops such as the nanopollutant which is generated during the manufacturing of nanomaterials, may lead to unwanted hazards to environment by penetrating into plants or animal tissue.

Related Journals of Implementation and Implications of Nanomedicine

Journalof Nanotechnology: Nanomedicine & Nanobiotechnology,AustinJournal of Nanomedicine & Nanotechnology, Biosensors Journal, Journal of Tissue Science & Engineering, Nanomedicine: Nanotechnology, Biology, and Medicine, Nanomedicine, International Journal of Nanomedicine, Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, Artificial Cells, Nanomedicine and Biotechnology, Journal of Nanomedicine and Nanotechnology, European Journal of Nanomedicine, Open Nanomedicine Journal

One particular type of nanoparticle involves the use of liposomes as drug molecule carriers. The diagram on the right shows a standard liposome. It has a phospholipid bilayer separating the interior from the exterior of the cell.

Related Journals of Lipid bases Nanoparticles

TheOpen Nanomedicine Journal, CancerNanomedicine

Nanobiopharmaceutics is the application of nanotechnology into the world of medicine. It is an inter-disciplinary field involving the usage of nanoparticles to deliver biopharmaceutical products into the body. It involves knowledge from nanobiotechnology, biotechnology and biopharmaceutics.

Related Journals of Nanobiopharmaceuticals

Journalof Nanotoxicology and Nanomedicine, GlobalJournal of Nanomedicine

Nanoemulisers are another form for nanoparticle delivery systems using oil-in-water emulsions done on a nano-scale. This process uses common biocompatible oils such as triglycerides and fatty acids, and combines them with water and surface-coating surfactants.

Related Journals of Nanoemulsions

HenryJournal of Nanoscience, Nanomedicine& Nanobiology, Journalof Biosensors & Bioelectronics, NanotechnologyLaw andBusiness, Journal ofNanotechnologyin Engineering andMedicine, Nanotechnologyand Precision Engineering,Nanomaterials andNanotechnology,NanotechnologyPerceptions, NanoscienceandNanotechnology- Asia International Journal ofGreenNanotechnology, RSC Nanoscience andNanotechnology

Targeted medicine for the treatment of cancer can be obtained with the application of nanotechnology in gene-delivery method. With the use of nanocarriers genes can be administered into the target cells. With the use of Solid lipid nanoparticles as potential tools for gene therapy, in vivo protein expression was observed after intravenous administration.

Related Journals of Nanomedical Tools in Gene Therapy

SM Journal of Nanotechnology and Nanomedicine, Nanomedicine Journal, Journal of Nanomaterials & Molecular Nanotechnology, Nano Research & Applications, IEEE Transactions onNanotechnology, Journal of BiomedicalNanotechnology, International Journal ofNanotechnology, Beilstein Journal ofNanotechnology, Recent Patents onNanotechnology, e-Journal of Surface Science andNanotechnology, Nanoscience andNanotechnologyLetters, Nanotechnology, Science and Applications

Disease diagnosis, target specific drug delivery, molecular imaging is possible with the application of nanotechnology in medicine. Nanoparticles are engineered in an extent that they get attracted to the diseased cells and allows for detection of disease. Nanomedicine is applicable in drug delivery, therapy techniques, diagnostic techniques, anti-microbial techniques, cell repair.

Related Journals of Nanomedicine Applications

NanomedicineJournal, InternationalJournal of Nanomedicine, Journal of Biomimetics Biomaterials and Tissue Engineering, Advances in Natural Sciences: Nanoscience and Nanotechnology, Nanotechnology Law and Business, Interdisciplinary Reviews:Nanomedicineand Nanobiotechnology, Artificial Cells,Nanomedicineand Biotechnology, Journal of Nanomedicine and Nanotechnology, European Journal ofNanomedicine, OpenNanomedicineJournal

Nanomedicine is a novel medical application extended in the field of cancer studies. A wide range of nanotechnology tools have provided platform for the early diagnosis, improved imaging and targeted therapies. Cancer nanomedicine has remained progressively applied in areas including nanodrug delivery systems, nanopharmaceuticals, and nanoanalytical contrast reagents in laboratory and animal model research.

Related Journals of Nanomedicine in Cancer

Nanomedicine:Nanotechnology, Biologyand Medicine, Journalof Nanomedicine & Nanotechnology, International JournalofNanotechnology, Beilstein Journal ofNanotechnology,Recent Patents onNanotechnology, e-Journal of Surface ScienceandNanotechnology, NanoscienceandNanotechnologyLetters, Nanotechnology, Science andApplications

Nanomedicine is playing a key role in the growing part of pharmaceutical research and development (R&D), largely in the form of nanoparticle-based delivery systems for drugs. Researchers are developing advanced drug delivery systems by researching drug conjugates and nanoformulations; polymer, lipid, peptide, and protein nanoparticles; biopharmaceutical protein engineering and chemical conjugation; and self-assembly and processing of nanomedicines.

Related Journals of Nanomedicine in Drug Discovery

InternationalJournal of Nanomedicine, EuropeanJournal of Nanomedicine Nanomedicine, Journalof Tissue Science & Engineering, Journal ofBiochips & Tissue Chips, Nanomedicine: Nanotechnology,Biology, and Medicine, Nanomedicine, International JournalofNanomedicine, InterdisciplinaryReviews:Nanomedicineand Nanobiotechnology, ArtificialCells,Nanomedicineand Biotechnology, Journal ofNanomedicine and Nanotechnology, European JournalofNanomedicine

Nanoparticles are 1 and 100 nanometers in size particles that are used in medicine which delivers drug specifically to the target cells. These nanoparticles have many advantages over the age old drug delivery systems as nanoparticles are more specific drug delivery systems, reduced toxic effects while continuing therapeutic effects, biocompatible and faster and safe medicine. Some of the major application of these nanoparticles are protein filled nanoparticles, cerium oxide nanoparticles that acts as an antioxidant, chemotherapy drugs attached to nanodiamonds, nickel nanoparticles and a polymer, low cost electrodes for fuel cells.

Related Journals of Nanoparticles

Journalof Interdisciplinary Nanomedicine, Journalof Nanomedicine Research, Journalof Nanomedicine & Nanotechnology, Nanotechnology, Scienceand Applications, Advances in Natural Sciences: NanoscienceandNanotechnology, NanotechnologyLaw andBusiness, Journal ofNanotechnologyin Engineering andMedicine, Nanotechnologyand Precision Engineering,CancerNanotechnology, Journal ofNanotechnology,International Journal of GreenNanotechnology: Biomedicine

Polymeric nanoparticle delivery is the mechanism for the transport of polymer-based nanoparticles across the blood-brain barrier and has been characterized as receptor-mediated endocytosis by the brain capillary endothelial cells.

Related Journals of Polymeric Nanoparticle Delivery

JSMNanotechnology & Nanomedicine, InternationalJournal of Nanomaterials, Journalof Nanomedicine & Nanotechnology, Nanomedicine:Nanotechnology, Biology, and Medicine, Nanomedicine, InternationalJournal ofNanomedicine, InterdisciplinaryReviews:Nanomedicineand Nanobiotechnology, ArtificialCells,Nanomedicineand Biotechnology, Journal ofNanomedicine and Nanotechnology, European JournalofNanomedicine, OpenNanomedicineJournal

Polymeric nanoparticles, self-emulsifying delivery systems, liposomes, microemulsions, micellar solutions and recently solid lipid nanoparticles (SLN) have been exploited as probable possibilities as carriers for oral intestinal lymphatic delivery.

Related Journals of Solid Lipid Nanoparticles

Nanotechnologyand Nanomedicine, InternationalJournal of Nanomedicine and Nanosurgery, Journalof Biosensors & Bioelectronics,OpenNanomedicineJournal, NatureNanotechnology,Nanotechnology, Journal of Nanoscience and Nanotechnology,Nanomedicine:Nanotechnology, Biology, and Medicine, IEEETransactions onNanotechnology, Journal ofBiomedicalNanotechnology, International JournalofNanotechnology

Immunotherapy has a great significance in the cancer therapy. Nanotechnology-based therapeutic agents and drug carriers are formulated so that they attack only the cancer cells. Nanocarriers using the DNA, RNA, proteins have shown better results in cancer immunotherapy.

Related Journals of Therapeutic Agents

Journalof Nanotechnology: Nanomedicine & Nanobiotechnology,AustinJournal of Nanomedicine & Nanotechnology, Journal of Genetic Syndromes & Gene Therapy, Journal of BiomedicalNanotechnology, International Journal ofNanotechnology, Beilstein Journal ofNanotechnology, Recent Patents onNanotechnology, e-Journal of Surface Science andNanotechnology, Nanoscience andNanotechnologyLetters, Nanotechnology, Science and Applications, Advances in Natural Sciences: Nanoscience andNanotechnology

Nanotoxicology is the study of the toxicity of nanomaterials. Because of quantum size effects and large surface area to volume ratio, nanomaterials have unique properties compared with their larger counterparts.

Related Journals of Toxicity of Nanomaterials

TheOpen Nanomedicine Journal, CancerNanomedicine, Journalof Biosensors & Bioelectronics, JournalofNanotechnology, International Journal ofGreenNanotechnology: Biomedicine, NanomaterialsandNanotechnology, NanotechnologyPerceptions,International Journal of GreenNanotechnology: Physics andChemistry, Nanoscience andNanotechnology- Asia

See the original post here:
Journal of Nanomedicine & Biotherapeutic Discovery

Comprehensive Analysis On Nanomedicine Market Based On Types And Application The Bisouv Network – The Bisouv Network

Posted on by

The Nanomedicine market report provides a detailed analysis of the emerging trends, opportunities, and as well as the challenges in the market. This extensive report sheds light on the latest developments, market drivers, and competitive analysis to help the new entrants and emerging players to make crucial decisions.

Besides this, the market research report presents insights on consumer behavior, regulatory policies, and supply & demand scenario to provide a holistic view of the market. The primitive aim of the report is to represent the critical data and figures of the market concisely and layout top winning strategies to aid industry players to leverage their market position.

Get Free Sample Report + All Related Graphs & Charts: https://dataintelo.com/request-sample/?reportId=81345

The dedicated research team has included Porters Five Point Force analysis to tailor the Nanomedicine Market. They have conducted interviews with industry experts to provide accurate predictions and better insights in a detailed manner. The research report covers the latest advancements that have overhauled the market dynamics while examined the threats which has impacted the overall market.

Key Answers Captured in the Study are

Complete Purchase of Latest Version Global Nanomedicine Market Study with COVID-19 Impact Analysis: https://dataintelo.com/checkout/?reportId=81345

Important Features that are under offering & key highlights of the report:

Detailed overview of Nanomedicine

Changing market dynamics of the industry

In-depth market segmentation by Type, Application, etc.

Historical, current, and projected market size in terms of volume and value

Recent industry trends and developments

Competitive landscape of Nanomedicine

Strategies of key players and product offerings

Potential and niche segments/regions exhibiting promising growth

A neutral perspective towards Nanomedicine performance

Market players information to sustain and enhance their footprint

Ask for the discount @ https://dataintelo.com/ask-for-discount/?reportId=81345

Research Objectives

To analyze and forecast the Worldwide Nanomedicine, in terms of value and volume.

Which segment has the potential to gain the highest market share?

To help decision-makers from a new offer perspective and benchmark existing marketing strategy.

Correlate cost structure historical data with key business segments.

Analyze marketing contribution and customer acquisition by up-selling and cross-selling.

Identifying Influencing factors keeping Worldwide Nanomedicine Intense, factored with periodic analysis of CR4 & CR8 concentration ratio & HHI Index.

Important Features that are under offering & key highlights of the report:

1) Does the study cover COVID-19 Impact Analysis and its effect on Growth %?

Yes, the overall industry has seen quite a big impact due to slowdown and shutdown in the production line & supply chain. The study covers a separate qualitative chapter on COVID-19 Impact analysis. Additionally, it also provides before and after the scenario of COVID-19 on sales growth & market size estimation to better analyze the exact scenario of the industry.

2) How companies are selected or profiled in the report?

List of some players that are profiled in the report include:

CombimatrixAblynxAbraxis BioscienceCelgeneMallinckrodtArrowhead ResearchGE HealthcareMerckPfizerNanosphereEpeius BiotechnologiesCytimmune SciencesNanospectra Biosciences

Usually, we follow NAICS Industry standards and validate company profile with product mapping to filter relevant Industry players, furthermore the list is sorted to come up with a sample size of at least 50 to 100 companies having greater topline value to get their segment revenue for market estimation.

** List of companies mentioned may vary in the final report subject to Name Change / Merger etc.

3) Can we add or profiled a new company as per our needs?

Yes, we can add or profile a new company as per client need in the report, provided it is available in our coverage list as mentioned in answer to Question 1 and after feasibility run, final confirmation will be provided by the research team checking the constraints related to the difficulty of survey.

4) Can we narrow the available business segments?

Yes, depending upon the data availability and feasibility check by our Research Analyst, a further breakdown in business segments by end-use application or product type can be provided (If applicable) by Revenue Size or Volume*.

Nanomedicine market segmentation

The Study is segmented by following Product Type:

Quantum dotsNanoparticlesNanoshellsNanotubesNanodevices

Major applications/end-users industry are as follows:

Segmentation encompasses oncologyInfectious diseasesCardiologyOrthopedicsOthers

5) Can a specific country of interest be added? What all regional segmentation covered?

Yes, Country-level splits can be modified in the study as per objectives. Currently, the research report gives special attention and focus on the following regions:

North America [United States, Canada, Mexico], Asia-Pacific [China, India, Japan, South Korea, Australia, Indonesia, Malaysia, Philippines, Thailand, Vietnam], Europe [Germany, France, UK, Italy, Russia, Rest of Europe], South America [Brazil, Argentina, Rest of South America], Middle East & Africa [GCC Countries, Turkey, Egypt, South Africa, Rest of the Middle East & Africa]

** One country of specific interest can be included at no added cost. For inclusion of more regional segment quotes will vary.

Get on the call with our research analyst if you have any particular doubts before buying the report @ https://dataintelo.com/enquiry-before-buying/?reportId=81345

About US:

DATAINTELO has set its benchmark in the market research industry by providing syndicated and customized research report to the clients. The database of the company is updated on a daily basis to prompt the clients with the latest trends and in-depth analysis of the industry.

Our pool of database contains various industry verticals that include: IT & Telecom, Food Beverage, Automotive, Healthcare, Chemicals and Energy, Consumer foods, Food and beverages, and many more. Each and every report goes through the proper research methodology, validated from the professionals and analysts to ensure the eminent quality reports.

Contact Info:

Name: Alex Mathews

Address: 500 East E Street, Ontario,

CA 91764, United States.

Phone No: USA: +1 909 545 6473

Email:[emailprotected]

Website:https://dataintelo

See more here:
Comprehensive Analysis On Nanomedicine Market Based On Types And Application The Bisouv Network - The Bisouv Network

Quilts for pancreatic cancer patients and research – University of Strathclyde

Posted on by

Chemistry researchers at the University of Strathclyde are aiming to raise awareness of pancreatic cancer with the use of specially-made quilts.

Fellow cancer researchers across the UK are being asked to send diagrams illustrating their work. These will then be used as the patterns for quilts made by skilled crafters.

After the project is concluded, the Strathclyde researchers hope to be able to display the quilts in an exhibition, which may be held online if a physical exhibition is not possible. The quilts will then be donated to local pancreatic cancer patients

The project, titled Quilts4Cancer, is being funded through a grant of 4700 from the Royal Society of Chemistry.

Nearly 9,500 people each year are diagnosed with pancreatic cancer in the UK.

Dr Clare Hoskins, a Reader in Strathclydes Department of Pure and Applied Chemistry, is leading Quilts4Cancer, along with Dr Kirsty Ross, the Departments Outreach Officer. The programme is being launched to coincide with Pancreatic Cancer Awareness Month in November.

Dr Hoskins said: Funds for cancer research have dropped significantly in the pandemic but we aim to raise awareness of chemistry research across the UK towards better therapies for pancreatic cancer, as well as raising awareness of its signs and symptoms.

We chose to have quilts made because its known that chemotherapy patients get cold during their treatment. The therapy has serious side effects but we want to raise awareness of the new technology and compounds coming through; a lot of work is being done on making treatment safer, with fewer side effects.

Were asking for researchers in the chemical sciences to send simple diagrams based on their research, with small summaries of what it is and who is carrying it out. It could show the chemical structures of treatments or technology such as ultrasound equipment.

My design illustrates my research in laser-activated nanomedicine. It shows nanoparticles which have been found to penetrate deep into pancreatic tumour tissue, allowing for drug treatments to reach the site where they are required and help reduce the unpleasant side effects. These nanoparticles act as chaperones for the drug molecules, carrying their cargo past the bodys defence systems and to their target site.

On arrival, a laser beam activates them to release their drugs, making them more effective than conventional chemotherapy. The nanocarriers themselves are relatively simple and cheap to make and they can be easily tailored for different uses and cancer types.

Dr Hoskins and Dr Ross have created a Quilts4Cancer Facebook page. Anyone wishing to participate in the project can contact Dr Hoskins.

The project will hold evening stitching sessions throughout November. Register for the sessions.

Read more:
Quilts for pancreatic cancer patients and research - University of Strathclyde

Why Exosomes Are Being Explored as Diagnostic and Therapeutic Tools – Technology Networks

Posted on by

In 1983, two separate research groups reported novel observations regarding small, extracellular vesicles released by maturing red blood cells.1,2 Five years later, the vesicles were named exosomes by Rose Johnstone, an author from one of the original studies.3 On reflection, Johnstone describes her groups early discovery as somewhat accidental, explaining they stumbled upon exosomes when they were looking for an appropriate system to identify a specific transport protein.4 According to Johnstone, reports of the observation were initially met with disbelieving eyes.Now, the initial skepticism has been overcome; instead of being considered an artifact, exosome formation is now accepted as a natural phenomenon. As biologists race to unlock the potential of exosomes, research in the field continues to gain momentum; enter exosomes in the PubMed search box and you will see over 4000 results from 2020 alone (up from 265 results in 2010). In this article, we provide an overview of the biology of exosomes and explore their potential uses as diagnostic and therapeutic tools a market now valued at over $41 million and projected to reach $358.91 million by 2027.

Live reporters like these can reveal unexpected cellular behaviors by allowing real-time visualization of the secretion and interaction of exosomes with cells. Although we know exosomes are important for directional migration, we were surprised by how closely the cells followed the exosome trails as if the exosomes were releasing an attracting factor or pheromone.

For Wafa Al-Jamal, reader in nanomedicine and drug delivery at Queens University Belfast School of Pharmacy, Northern Ireland, UK, exosome mimetics represent a way forward in her mission to develop personalized, effective and safe nanomedicines targeting metastatic prostate cancer. Our vision, says Al-Jamal, is to engineer targeted exosome mimetics from patients' blood cells, so the treatment is customized for each patient. Al-Jamal notes how challenging it has been to deliver effective doses of chemotherapeutics to metastatic lesions especially in bone without causing toxicity to healthy tissues. The approach, described recently in the Journal of Controlled Release, aims to improve drug delivery by targeting drug-loaded exosome mimetics to advanced and metastatic prostate cancer lesions by combining the intrinsic affinity of exosome mimetics with active targeting via prostate-specific membrane antigen (PSMA).29Our approach is based on filtering whole monocyte cells into smaller cell-mimetic vesicles using different pore size membranes, which generates vesicles similar to naturally-secreted extracellular vesicles (e.g., exosomes) but accelerates production and increases yield, explains Al-Jamal. Moreover, our approach aims to prepare targeted vesicles expressing a prostate-targeting ligand on the cells' surface, eliminating the chemical procedures that would otherwise be required to attach the targeting ligand to the vesicles surface.

Exosome mimetics also provide an opportunity for theranostics, i.e., the combination of diagnostic and therapeutic applications to predict therapy outcomes in animal models and patients. Al-Jamal explains how the co-delivery of diagnostics and therapeutics in a single nanocarrier could be achieved: Due to the vesicular nature of exosome mimetics, drugs and imaging agents could be co-loaded into the same vesicles. Alternatively, imaging agents could be conjugated to the vesicles surface.

More:
Why Exosomes Are Being Explored as Diagnostic and Therapeutic Tools - Technology Networks

Redefining the status quo in healthcare – The Business Times

Posted on by

When Dean Ho looks into the future, he sees a world where more people have access to higher quality healthcare at lower costs. Some may call him an optimist, but the research director is in a better position than most to believe in this somewhat utopian vision.

As director at a research institute that is personalising patient care and using digital medicine to usher in a new frontier of healthcare, Dr Ho is leading efforts to develop artificial intelligence (AI)-based solutions to design clinical trials for various purposes, including novel drug development and more recently, formulating optimal drug combinations to treat the Covid-19 virus.

Dr Ho, 41, who moved to Singapore with his family from the United States in 2018, says: "We are working hard to scale the validation, deployment, and implementation of our AI-based platforms.

"One of our major goals is to demonstrate that we can dramatically reduce the cost of optimal drug combination development, with orders of magnitude reduction in costs and bringing AI-optimised treatment outcomes to patients years faster, particularly in the area of oncology. We are excited about what's on the horizon."

His team has been using a platform called IDentif.AI to determine optimal combination therapies that can be clinically-administered to treat Covid-19 patients. "From our first studies, we were able to identify an extensive list of possible combinations, ranked based on their efficiency at countering infection from a patient-derived SARS-CoV-2 live virus."

This list enables clinicians to select potential combinations that may or may not contain certain drugs due to drug shortages or a patient's pre-existing conditions. "This allows for a substantial level of actionability and versatility for clinicians, as they have a broad spectrum of treatment options," he explains.

The response has been encouraging so far. Already, multiple clinical communities across the globe have reached out to his team for their results, which have provided helpful guidance.

The team ultimately aims to work with multiple partners to develop IDentif.AI-pinpointed combinations based on a large collection of potential therapies. They also plan to develop a public database of these combinations for the benefit of the community. "In the event we need additional combinations in the future, we will be ready," he says.

Curating precision treatments

Dr Ho's pandemic-related work is just part of his broader mission to leverage technologies such as AI and nanotechnology to create precision and personalised medicine for the benefit of patients.

One of his more notable achievements is the creation of Curate.ai, an AI platform developed over about five years by a research team led by Dr Ho. As each individual's response to medication is unique and changing, Curate.ai uses a patient's data - such as how a tumour changes in size following a certain drug dosage - to generate a profile that is able to recommend the optimal drug dosage for this person at any point in time.

This method of dosing is designed to improve the efficacy and safety of treatments.

In 2018, Curate.ai's recommended drug dosage for a prostate cancer patient successfully reduced the size of his tumour. According to Dr Ho, his team's AI solutions are unique in that they use actual experimental data from studies to optimise the right drugs and doses. As a result, these platforms have already been taken to the clinic for multiple studies, he reveals.

"Importantly, by rapidly optimising how we develop these treatments or administer these treatments, we have an opportunity to markedly accelerate the delivery of these optimised therapies to patients, potentially reducing the cost of care while realising substantially improved treatment outcomes. Of note, our AI platforms can be broadly deployed against a broad spectrum of disease indications, so that we can continue to help as many patients as possible," he says.

Going big with nanotech

Dr Ho is also a pioneer in nanomedicine, with his team spearheading the use of nanoscopic "diamonds" that carry drugs to diseased cells in the body to treat cancer. Together with collaborators, they also developed a magnetic resonance imaging agent that dramatically improves imaging brightness, substantially reducing the amount of imaging agent required.

"Nanotechnology is exciting because the materials that we use are versatile and can be coated with a broad spectrum of therapies as well as imaging agents, and these nanomaterials can often markedly improve the efficiency and safety of drug treatment or imaging efficiency," explains Dr Ho.

For his AI-related work in personalised and precision medicine, as well as in the areas of nanomedicine, Dr Ho was the only Singapore-based academic inventor elected in 2018 as a fellow of the United States National Academy of Inventors, the highest professional accolade for academic inventors.

"I'm hoping that our aspirations of redefining the status quo in healthcare, and making practice-changing advances in medicine will have helped as many people as possible."

Family inspiration

One of Dr Ho's clinical trials was a collaborative project with his father focused on optimising drug therapy for liver transplant patients to prevent organ rejection.

"We were able to use AI to recommend appropriate dosages, but not only that, we could see an immediate and real benefit: patients could be discharged from intensive care up to a month earlier," he says.

"It was amazing to work with my dad to realise these outcomes for patients."

Indeed, the father of two aligns his work closely with how he views family. "We're often approached by families and communities who need help for a loved one.

"As a father, I want my children to know I'll always be there to help them when they need it. That's the same hope I have for the technologies we've developed."

Dr Ho was born and raised in Los Angeles and attended the University of California, Los Angeles (UCLA), graduating with a PhD in biomedical engineering. Before relocating to Singapore in 2018, he spent six years as a professor at UCLA.

His parents had migrated to the United States to pursue their education, and he learnt from them the importance of using one's achievements to give back to society. His father was a career innovator in various fields, from biomedical to aerospace engineering, and treated his team as family, while his mother is a gifted artist and speaker.

"My parents were a huge inspiration for me growing up. Both of my parents inspired me to give back to the community, and being surrounded by their diverse strengths has been amazing," he says.

His experiences growing up also taught him the importance of fostering a close-knit team at work, and being a responsible and nurturing parent and husband. He describes his son Ethan as an inquisitive child who adores sharks and all marine creatures, while his daughter is free-spirited and creative. He met his wife, Sarah Ahn, in college when both of them were pursuing biomedical doctorates, although she would later switch careers to study fashion design and establish her own label, NAMI.

It takes a village

Several months after the family moved to Singapore, Dr Ho's wife was diagnosed with a brain tumour. "After my wife's diagnosis, I was completely and utterly lost. I'm usually the one who knows what's next, because that's what I do. Now we were on the other side."

Thankfully, with the help of their community, Sarah was able to recover. "It takes a community to weather adversity. The minute we found out about Sarah's diagnosis, I was on the phone with so many people who went on to collectively play a role in saving her life and getting her back on her feet.

"We were away from our immediate family, but our community of supporters became a new family for us. We are so deeply grateful for that," he recalls.

Dr Ho believes that community will also be key in achieving his goal of advancing healthcare, as it will take a collective effort from different stakeholders in the sector's ecosystem. "Our team strongly believes that technology alone won't markedly advance healthcare. It takes the seamless integration of multiple disciplines and skill sets."

He notes that a key challenge in his work is to pair the AI platforms his team has developed with stakeholders that will play a vital role in ensuring that they can be integrated into healthcare workflows.

This includes doctor and nursing teams, healthcare economists, behavioural scientists, regulators, payer and reimbursement communities, as well as the patients and patient advocacy groups, among many others.

He cites these partners, as well as his own team members, as inspirations. "I consider this community my family, and collaborating with them has been an honour. Our work together is a mutual learning experience, and it has taken mutual inspiration to bring us to the point where we are now seeing the promise of clinical impact."

Leaving a legacy

While Dr Ho is well on his way to making a mark in the healthcare world, he is also focused on crafting a legacy that is far more personal in nature; and that is to ensure that his children have the means to achieve their own dreams.

He says: "To me, legacy planning means having the foresight to think ahead and provide peace of mind for our future generations so that they won't have to worry about not having the necessary means to support their aspirations. In the case of our children, we want to solidify their access to the financial means for limitless educational goals."

Crafting a legacy across generations

WHETHER it's as bold as changing the future of healthcare, or as intimate as giving your loved ones the means to realise their dreams, there are many paths to crafting one's legacy.

Whatever form it takes, your legacy is a testimony that deserves to live on.

At Opus by Prudential, we understand that it sometimes takes a community to help you make a lasting impact. That's why we offer you seamless support and services to take care of your wealth planning and protection needs - from VIP medical services at one of Singapore's finest healthcare clinics to swift underwriting and dedicated case management, plus access to our panel of value-added services advisors.

Dr Dean Ho is one client who has experienced the exceptional support that Opus professionals can provide. "When my wife, Sarah, was diagnosed with a brain tumour, our family's shock was extraordinarily disorienting. Estella, our Opus Financial Consultant, was one of the very first people we spoke to," recalls Dr Ho. "Her being there for us in the very beginning was an amazing source of security for us. She helped us navigate the process of preparing our documents, but most of all, she became family during the process.

"She was always accessible, and would often check in with us to ask if there was any way that she could help."

With our tailored expertise, Opus by Prudential can help you uniquely plan and preserve your wealth, protect your assets, safeguard your health and retire with ease. No matter what path you take, or how you wish to be remembered, we can help you forge a legacy that will make its mark across generations.

Find out more about legacy planning from an Opus by Prudential Private Wealth Consultant

Read the original here:
Redefining the status quo in healthcare - The Business Times

Healthcare Nanotechnology (Nanomedicine) Market Forecasted To Surpass The Value Of US$ XX Mn/Bn By 2015 2021 – Owned

Posted on by

New Study on the Global Healthcare Nanotechnology (Nanomedicine) Market by PMR

PMR recently published a market study that sheds light on the growth prospects of the global Healthcare Nanotechnology (Nanomedicine) market during the forecast period (20XX-20XX). In addition, a methodical and systematic approach adopted by the analysts while curating the market study ensures that the presented study adds value to the business of our customers. The report provides a thorough evaluation of the latest trends, market drivers, opportunities, and challenges within the global Healthcare Nanotechnology (Nanomedicine) market.

As per the report, the global Healthcare Nanotechnology (Nanomedicine) market is expected to grow at a CAGR of ~XX% during the stipulated timeframe owing to a range of factors including, favorable government policies, and growing awareness related to the Healthcare Nanotechnology (Nanomedicine) , surge in research and development and more.

Request Sample Report @ https://www.persistencemarketresearch.co/samples/6370

Resourceful insights enclosed in the report:

Competitive Outlook

The competitive outlook section provides valuable information related to the different companies operating in the current Healthcare Nanotechnology (Nanomedicine) market landscape. The market share, product portfolio, pricing strategy, sales and distribution channels of each company is discussed in the report.

Request Report Methodology @ https://www.persistencemarketresearch.co/methodology/6370

Regional Assessment

The presented market study touches upon the market scenario in different regions and provides a deep understanding of the influence of micro and macro-economic factors on the prospects of the market in each region.

Key players in the global nanomedicine market include: Abbott Laboratories, CombiMatrix Corporation, GE Healthcare, Sigma-Tau Pharmaceuticals, Inc., Johnson & Johnson, Mallinckrodt plc, Merck & Company, Inc., Nanosphere, Inc., Pfizer, Inc., Celgene Corporation, Teva Pharmaceutical Industries Ltd., and UCB (Union chimique belge) S.A.

Key geographies evaluated in this report are:

Key features of this report

For any queries get in touch with Industry Expert @ https://www.persistencemarketresearch.co/ask-an-expert/6370

The market report addresses the following queries related to the Healthcare Nanotechnology (Nanomedicine) market:

Go here to see the original:
Healthcare Nanotechnology (Nanomedicine) Market Forecasted To Surpass The Value Of US$ XX Mn/Bn By 2015 2021 - Owned

Nanorobotics Market 2020 : Analysis by Geographical Regions, Type and Application Till 2025 – The Daily Chronicle

Posted on by

Nanorobotics Industry Analysis 2020

TheNanorobotics Marketreport enlightens its readers about its products, applications, and specifications. The research enlists key companies operating in the market and also highlights the roadmap adopted by the companies to consolidate their position in the market.By extensive usage of SWOT analysis and Porters five force analysis tools, the strengths, weaknesses, opportunities, and combination of key companies are comprehensively deduced and referenced in the report.Every single leading player in this global market is profiled with their related details such as product types, business overview, sales, manufacturing base, applications, and other specifications.

Major Market Players Covered In This Report:, Bruker, JEOL, Thermo Fisher Scientific, Ginkgo Bioworks, Oxford Instruments, EV Group, Imina Technologies, Toronto Nano Instrumentation, Klocke Nanotechnik, Kleindiek Nanotechnik

Click Here To Access The Sample Report:https://grandviewreport.com/sample/23160

NanoroboticsMarket has exhibited continuous growth in the recent past and is projected to grow even more throughout the forecast. The analysis presents an exhaustive assessment of the market and comprises Future trends, Current Growth Factors, attentive opinions, facts, historical information, in addition to statistically supported and trade validated market information.

The Global NanoroboticsMarket Can Be Segmented As

The key product type of Nanoroboticsmarket are:, Nanomanipulator, Bio-Nanorobotics, Magnetically Guided, Bacteria-Based

NanoroboticsMarket Outlook by Applications:, Nanomedicine, Biomedical, Mechanical

To Get This Report At Beneficial Rates:https://grandviewreport.com/discount/23160

The Nanoroboticsmarket comprising of well-established international vendors is giving heavy competition to new players in the market as they struggle with technological development, reliability and quality problems the analysis report examines the expansion, market size, key segments, trade share, application, and key drivers.

Key players within the Nanoroboticsmarket are identified through secondary analysis, and their market shares are determined through primary and secondary analysis. The report encloses a basic summary of the trade lifecycle, definitions, classifications, applications, and trade chain structure. Each of these factors can facilitate leading players to perceive the scope of the Market, what unique characteristics it offers and the manner in which it will fulfill a customers need.

By Company Profile, Product Image and Specification, Product Application Analysis, Production Capability, Price Cost, Production Value, Contact Data are included in this research report.

What NanoroboticsMarket report offers:NanoroboticsMarket share assessments for the regional and country-level segmentsMarket share analysis of the highest trade playersNanoroboticsMarket Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and Recommendations)Strategic recommendations on key business segments

The Report Answers Following Questions:Over successive few years, which Nanoroboticsapplication segment can perform well?Within which market, the businesses ought to establish a presence?Which product segments are exhibiting growth?What are the market restraints which are likely to impede the growth rate?However, market share changes their values by completely different producing brands?

To Know More About The Assumptions in This Market Report:http://grandviewreport.com/industry-growth/Nanorobotics-Market-23160

The report entails detailed profiling of each company, and information on capacity, production, price, revenue, cost, gross, gross margin, sales volume, sales revenue, consumption, growth rate, import, export, supply, future strategies, and the technological developments, are also included within the scope of the report. In the end, the NanoroboticsMarket Report delivers a conclusion which includes Breakdown and Data Triangulation, Consumer Needs/Customer Preference Change, Research Findings, Market Size Estimation, Data Source. These factors are expected to augment the overall business growth.

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like Asia, United States, Europe.

See the rest here:
Nanorobotics Market 2020 : Analysis by Geographical Regions, Type and Application Till 2025 - The Daily Chronicle

Medical News Today: How nanoparticles may drive the spread of cancer – Stock Daily Dish

Posted on by

New research finds that some nanomaterials that scientists use to combat cancer may have the opposite effect: to help tumors spread. The results reveal why this might occur and propose a way for us to turn this risk into a therapeutic advantage. Nanoparticles may make cancer cells (depicted here) divide and spread faster.

Nanotechnology has recently emerged as an innovative avenue for treating .

For instance, some researchers have devised that can seek out cancer cells and pulverize them from within.

Others, however, have used to deliver concentrated drugs in an extremely precise way, avoiding the side effects that conventional might cause.

But what are these nanocarriers made from, and could the materials that scientists use in nanomedicine help, rather than hinder, the spread of cancer?

Scientists most commonly use gold, titanium dioxide, silver, and silicon dioxide, among others, for therapeutic purposes.

However, the results of which now appear in the journal Nature Nanotechnology suggests that these nanomaterials could facilitate the spread of cancer cells by increasing the gap between blood vessel cells and allowing cancer cells to migrate more easily to new sites.

Researchers at the National University of Singapore (NUS) near Clementi reached this conclusion after studying several models of in rodents.

Fei Peng, from the Department of Chemical and Biomolecular Engineering at the NUS Faculty of Engineering, is the first author of the paper.

Peng and colleagues dubbed the phenomenon nanomaterials-induced endothelial leakiness (NanoEL). In their paper, they also suggest new ways in which drug developers could use this discovery to devise more effective therapies for cancer and other conditions.

Peng and team found that NanoEL speeds up the movement of cancer cells from the original site to new sites and helps the cancer cells that are already in motion evade blood circulation.

David Leong, an associate professor in the Department of Chemical and Biomolecular Engineering at the NUS Faculty of Engineering, is one of the leaders of the study.

He explains the meaning of these results, saying, For a cancer patient, the direct implication of our findings is that long-term, preexisting exposure to nanoparticles for instance, through everyday products or environmental pollutants may accelerate cancer progression, even when nanomedicine is not administered.

Nanoparticles may often be present in processed food and cosmetic products such as creams and lotions.

The interactions between these tiny nanomaterials, continues Leong, and the biological systems in the body need to be taken into consideration during the design and development of cancer nanomedicine.

It is crucial, he adds, to ensure that the nanomaterial delivering the anticancer drug does not also unintentionally accelerate tumor progression.

As new breakthroughs in nanomedicine unfold, we need to concurrently understand what causes these nanomaterials to trigger unexpected outcomes.

David Leong

The study authors also explain that we could harness the same mechanism that might represent a vulnerability in cancer treatment and drive tumor spread to achieve precisely the opposite effect.

Making blood vessels leakier, they say, may also facilitate the access of chemotherapy drugs or to damaged tissues.

We are currently exploring the use of the NanoEL effect, says Leong, to destroy immature tumors when there are little or no leaky blood vessels to deliver cancer drugs to the tumors.

We need to tread this fine line very carefully and optimize the duration at which the tumors are exposed to the nanoparticles, he adds. This could allow scientists to target the source of the disease before the cancer cells spread and become a highly refractory problem.

In addition to cancer, it may also be possible to apply the findings to other conditions that involve damaged organs and tissues.

Study co-leader Han Kiat Ho, of the Department of Pharmacy at NUS Faculty of Science, explains further.

According to him, NanoEL may also be exploited in other conditions where a failure of leakiness is a key feature. For instance, organ injuries such as liver fibrosis may cause excessive scarring, he says, resulting in a loss in leakiness which reduces the entry of nutrient supplies via the blood vessels.

View post:
Medical News Today: How nanoparticles may drive the spread of cancer - Stock Daily Dish

New Horizon 2020 Project B-SMART Develops RNA-based Therapy for Neurodegenerative Diseases – Cordis News

Posted on by

New European research project B-SMART targets RNA-based nanomedicines against Alzheimers and spinal and bulbar muscular atrophy (SBMA). The project aims to develop innovative nanotechnological RNA delivery systems to provide first causal therapy approach. B-SMART unites internationally renowned experts from 9 academic institutions and industrial partners coordinated by the University Medical Center Utrecht. The European Commission will invest 6 million over the next five years.

Nanomedical approaches can make a difference, providing new therapeutic options by helping drugs to enter the brain. Therefore, the multinational research project B-SMART sets out to provide an RNA-based therapy perspective for neurodegenerative diseases targeting the direct cause of the disease instead of its symptoms. The project is funded with a total budget of 6 million over the next five years by the European Commissions current Research Framework Programme Horizon 2020.

Transferring RNA therapeutics to the brain crossing the blood-cerebrospinal fluid barrier is a unique research endeavor, said Prof. Raymond Schiffelers from the University Medical Center Utrecht and coordinator of B-SMART. Finding a novel gateway to transport RNA to the brain will enable the development of causal therapies not only for Alzheimers, but for other diseases as well.

The consortium will work on specific nanocarriers protecting the RNA against enzymatic degradation while delivering it to the human brain. Crossing the brain-cerebrospinal fluid barrier requires specific targeting ligands, which will be based on heavy chain-only nanobodies that are smaller and more stable than conventional antibodies. The modular delivery system will be tested for safety and efficacy using in vitro and in vivo assays. To improve the nanomedicine manufacturability, B-SMART chose an operator-independent and scalable production method based on microfluidics.

B-SMART assembles a multi-national team of leading experts from 9 partnering institutions with long-standing experience in their respective fields. The B-SMART partners are involved in numerous exceptional national and international research programmes targeting close communication with the industry throughout all project stages in order to bridge the research-industry gap and enable timely exploitation of the project results.

B-SMART officially kicks off its activities with a first project meeting held in Utrecht on 1 and 2 February 2017.

B-SMART Partners Belgium VIB

Germany EURICE European Research and Project Office GmbH

Italy Istituto Biochimico Italiano Giovanni Lorenzini SpA

Netherlands University Medical Center Utrecht (Coordinator) 20 Med Therapeutics B.V.

Norway Stiftelsen SINTEF

Spain University of Santiago de Compostela

United Kingdom The Chancellor, Masters and Scholars of the University of Oxford Malvern Instruments Ltd

Project Details Name: B-SMART Brain-specific, Modular and Active RNA Therapeutics Start date: 2017-01-01 Duration: 60 months Budget: 6 million Coordination: University Medical Center Utrecht

Contact Coordinator University Medical Center Utrecht Prof. Raymond Schiffelers Email: R.Schiffelers@umcutrecht.nl Phone: +31 88 7556512

Project Management EURICE European Research and Project Office GmbH Corinna Hahn Email: c.hahn@eurice.eu Phone: +49 681 95 923362

This project has received funding from the European Unions Horizon 2020 research and innovation programme under grant agreement No 721058.

Original post:
New Horizon 2020 Project B-SMART Develops RNA-based Therapy for Neurodegenerative Diseases - Cordis News

Global Healthcare Nanotechnology Market 2019 by Manufacturers, Countries, Type and Application, Forecast to 2025 – Avon Lake Ledger

Posted on by

The "Healthcare Nanotechnology Market" report contains a wide-extending factual assessment for Healthcare Nanotechnology, which enables the customer to separate the future complicity and estimate the right execution. The advancement rate is evaluated dependent on insightful examination that gives credible information on the worldwide Healthcare Nanotechnology market. Imperatives and advancement points are merged together after a significant comprehension of the improvement of the Healthcare Nanotechnology market. The report is all around made by considering its essential information in the overall Healthcare Nanotechnology market, the essential components in charge of the interest for its products and administrations. Our best analysts have surveyed the Healthcare Nanotechnology market report with the reference of inventories and data given by the key players (Amgen, Teva Pharmaceuticals, Abbott, UCB, Roche, Celgene, Sanofi, Merck & Co, Biogen, Stryker, Gilead Sciences, Pfizer, 3M Company, Johnson & Johnson, Smith & Nephew, Leadiant Biosciences, Kyowa Hakko Kirin, Shire, Ipsen, Endo International), flexible sources and records that help to upgrade cognizance of the related methodological conditions.

Ask for sample link here: http://www.marketresearchstore.com/report/global-healthcare-nanotechnology-market-2019-by-manufacturers-countries-497770#RequestSample

The Healthcare Nanotechnology market report shows a point by point division (Nanomedicine, Nano Medical Devices, Nano Diagnosis, Other) of the overall market reliant on development, product type, application, and distinctive techniques and systems. The point-to-point elucidation of the Healthcare Nanotechnology market's assembling system, the usage of advancement, conclusions of the world market players, dealers and shippers' order, and the explicit business data and their improvement plans would help our customers for future courses of action and movement planned to make due in the Healthcare Nanotechnology market.

The Healthcare Nanotechnology market report includes the latest mechanical enhancements and new releases to engage our customers to the configuration, settle on taught business decisions, and complete their required executions in the future. The Healthcare Nanotechnology market report moreover focuses more on current business and present-day headways, future methodology changes, and open entryways for the Healthcare Nanotechnology market. Nearby progression frameworks and projections are one of the key segments that clear up overall execution and incorporate key geological analysis (Anticancer, CNS Product, Anti-infective, Other).

Inquire about the report here: http://www.marketresearchstore.com/report/global-healthcare-nanotechnology-market-2019-by-manufacturers-countries-497770#InquiryForBuying

The overall Healthcare Nanotechnology market is made with the fundamental and direct conclusion to exploit the Healthcare Nanotechnology market and participate in business progression for imperative business openings. The correct figures and the graphical depiction of the Healthcare Nanotechnology market are shown in a represented strategy. The report shows an examination of conceivable contention, current market designs and other basic characteristics all around the world.

Thanks for reading this article; you'll be able to additionally get individual chapter wise section or region wise report versions like North America, Europe, Asia-Pacific, South America, geographic area and continent.

Sorry! The Author has not filled his profile.

Read more here:
Global Healthcare Nanotechnology Market 2019 by Manufacturers, Countries, Type and Application, Forecast to 2025 - Avon Lake Ledger

Global Nanorobotics Market : Industry Analysis and Forecast (2018-2026) – The Market Expedition

Posted on by

Global Nanorobotics Marketwas valued at US$ 3.7 Bn in 2017 and is expected to reach US$ 9.2Bn by 2026, at a CAGR of 12.06%during a forecast period.Global Nanorobotics MarketDevelopments in nanotechnology coupled with demand for minimally aggressive procedures are expected to drive market growth over the forecast period. Nanobots possess likely in the medical sector for destroying cancerous cells at the genetic level. Increasing support for nanomedicine by many nations and the increasing geriatric population are factors which can augur market demand.

Utilization of nanobots in the ranostics can be beneficial for the market in the near future. A rise in miniaturization and demand for automation across various sectors are anticipated to fuel market growth. Training of new personnel to use nanobots can restrain market growth in the upcoming years.Nanomedicine application segment to grow at the highest CAGR during the forecast period. Nanorobotics is widely used in nanomedicine owning to its healthcare features. The large share of this application aspects to the large level of commercialization in the healthcare sector for drug delivery, in vivo imaging, biomaterial, in vitro diagnostic, active implants, and drug therapy.

North America region accounted for the largest share of 12.2%, in terms of value, of the nanorobotics market globally. Presence of many nanotechnology companies, well-developed healthcare infrastructure, and government initiatives to create patient awareness are factors driving the market. The U.S is anticipated to contribute to market revenue owing to the increase in cardiovascular diseases and the rising elderly populace.

REQUEST FOR FREE SAMPLE REPORT:https://www.maximizemarketresearch.com/request-sample/30888

Europe follows North America as the second biggest nanorobotics market. Presence of chronic diseases and the burgeoning population are factors expected to indicate the Europe nanobots market. Establishment of organizations to develop standards pertaining to nanotechnology can expand market growth. In 2018, DNA-Robotics, an organization including 12 European companies, has outlined steps to expedite production of nanobots on a large scale. These standards can help scale the market exponentially in the upcoming years.

A recent development in nanorobotics market: In March 2018, Thermo Fisher Scientific acquired Gatan, an exclusively owned subsidiary of Roper Technologies. Gatan is an electron microscopy solutions provider in the U.S, which accompaniments the Thermo Fisher Scientifics electron microscopy solutions business.In March 2017, Oxford Instruments (U.K) Asylum Research introduced its new SurfRider HQ-Series of high quality, budget-priced AFM probes, which are also existing in a model suitable for nanomechanical image mode.

The objective of the report is to present a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, industry-validated market data and projections with a suitable set of assumptions and methodology. The report also helps in understanding Global Nanorobotics Market dynamics, structure by identifying and analyzing the market segments and project the global market size. Further, the report also focuses on the competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence. The report also provides PEST analysis, PORTERs analysis, SWOT analysis to address the question of shareholders to prioritizing the efforts and investment in the near future to the emerging segment in the Global Nanorobotics Market.

DO INQUIRY BEFORE PURCHASING REPORT HERE:https://www.maximizemarketresearch.com/inquiry-before-buying/30888

Scope of the Global Nanorobotics Market

Global Nanorobotics Market, By Type

Nanomanipulatoro Electron Microscope (EM) Scanning Electron Microscope (SEM) Transmission Electron Microscope (TEM)o Scanning Probe Microscope (SPM) Atomic Force Microscopes (AFM) Scanning Tunneling Microscope (STM) Bio-Nanorobotics Magnetically Guided Bacteria-Based

Global Nanorobotics Market, By Application

Nanomedicine Biomedical Mechanical Others

Global Nanorobotics Market, By Region

North America Europe Asia Pacific Middle East and Africa South America

Key players operating in Global Nanorobotics Market:

Bruker JEOL Thermo Fisher Scientific Ginkgo Bioworks Oxford Instruments EV Group Imina Technologies Toronto Nano Instrumentation KlockeNanotechnik KleindiekNanotechnik Xidex Synthace Park Systems Smaract Nanonics Imaging

Key Innovators:

Novascan Technologies Angstrom Advanced Hummingbird Scientific NT-MDT Spectrum Instruments Witec

Browse Full Report with Facts and Figures of nanorobotics Market Report at:https://www.maximizemarketresearch.com/market-report/global-nanorobotics-market/30888/

MAJOR TOC OF THE REPORT

Chapter One: nanorobotics Market Overview

Chapter Two: Manufacturers Profiles

Chapter Three: Global nanorobotics Market Competition, by Players

Chapter Four: Global nanorobotics Market Size by Regions

Chapter Five: North America nanorobotics Revenue by Countries

Chapter Six: Europe nanorobotics Revenue by Countries

Chapter Seven: Asia-Pacific nanorobotics Revenue by Countries

Chapter Eight: South America nanorobotics Revenue by Countries

Chapter Nine: Middle East and Africa Revenue nanorobotics by Countries

Chapter Ten: Global nanorobotics Market Segment by Type

Chapter Eleven: Global nanorobotics Market Segment by Application

Chapter Twelve: Global nanorobotics Market Size Forecast (2019-2026)

About Us:

Maximize Market Research provides B2B and B2C market research on 20,000 high growth emerging technologies & opportunities in Chemical, Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

Contact info:

Name: Lumawant Godage

Organization: MAXIMIZE MARKET RESEARCH PVT. LTD.

Email: sales@maximizemarketresearch.com

Contact: +919607065656/ +919607195908

Website: http://www.maximizemarketresearch.com

Continue reading here:
Global Nanorobotics Market : Industry Analysis and Forecast (2018-2026) - The Market Expedition

IBM Research: Ninja polymers

Posted on by

Creating a hydrogel from the polymers

Through the precise tailoring of the ninja polymers, researchers were able to create macromolecules - molecular structures containing a large number of atoms - which combine water solubility, a positive charge, and biodegradability. When mixed with water and heated to normal body temperature, the polymers self-assemble, swelling into a synthetic hydrogel that is easy to manipulate.

When applied to contaminated surfaces, the hydrogel's positive charge attracts negatively charged microbial membranes, like stars and planets being pulled into a black hole. However, unlike other antimicrobials that target the internal machinery of bacteria to try to prevent it from replicating, this hydrogel destroys the bacteria by rupturing the bacteria's membrane, rendering it completely unable to regenerate or spread.

The hydrogel is comprised of more than 90 percent water, making it easy to handle and apply to surfaces. It also makes it potentially viable for eventual inclusion in applications like creams or injectable therapeutics for wound healing, implant and catheter coatings, skin infections or even orifice barriers. It is the first-ever to be biodegradable, biocompatible and non-toxic, potentially making it an ideal tool to combat serious health hazards facing hospital workers, visitors and patients.

The IBM scientists in the nanomedicine polymer program along with the Institute of Bioengineering and Nanotechnology have taken this research a step further and have made a nanomedicine breakthrough in which they converted common plastic materials like polyethylene terephthalate (PET) into non-toxic and biocompatible materials designed to specifically target and attack fungal infections.BCC Research reported that the treatment cost for fungal infections was $3 billion worldwide in 2010 andis expected to increase to $6 billion in 2014. In this breakthrough, the researchers identified a novel self-assembly process for broken down PET, the primary material in plastic water bottles, in which 'super' molecules are formed through a hydrogen bond and serve as drug carriers targeting fungal infections in the body. Demonstrating characteristics like electrostatic charge similar to polymers, the molecules are able to break through bacterial membranes and eradicate fungus, then biodegrade in the body naturally. This is important to treat eye infections associated with contact lenses, and bloodstream infections like Candida.

Follow this link:
IBM Research: Ninja polymers

CCNE | Northeastern University

Posted on by

Welcome!

The NIH-funded Northeastern University Center for Translational Cancer Nanomedicine (CTCN) was established in September 2010 as part of Phase 2 of the National Cancer Institute's Alliance for Nanotechnology in Cancer program with collaborators at Beth Israel Deaconess Hospital; Harvard Medical School; Tufts University, Auburn University and Nemucore Medical Innovations, Inc. The CTCN will utilize the support and facilities of the NU-based Center for High-rate Nanomanufacturing.

Northeastern University CTCN is one of only nine Centers of Cancer Nanotechnology Excellence (CCNE) across the country that has been awarded a five-year $13.5 million grant from the NCI Alliance in an open nationwide competition.

Building upon Northeasterns strong base of interdisciplinary nanotechnology research, the center will create new drugs that target cancer cells, advance technology on how nanocarriers deliver these drugs, and utilize imaging tools that track how they travel through the body. To enable the translation of these nanomedicines from bench to bedside, test batches of the nanopreparations will be developed for preclinical use to meet FDA standards for further clinical testing. The team will also develop semi-industrial and industrial processes to scale up their production.

Cross-disciplinary collaboration will enable integration of the fundamental biological knowledge base with physical science and engineering approaches for intimate involvement in scale-up and manufacture to rapidly translate bench research into animal testing and GMP production and to narrow the gap between discovery and development of anticancer therapeutics. The CTCN will concentrate on multifunctional, targeted devices that will bypass current biological barriers to delivery of multiple therapeutic agents at high local concentrations, with appropriate timing, directly to cancer cells.

Read the original:
CCNE | Northeastern University

Ethical Issues & Stakeholders Attitudes Towards Code of Conduct in Nanomedicine – Video

Posted on by


Ethical Issues Stakeholders Attitudes Towards Code of Conduct in Nanomedicine
Lecture of Dr. Iona Ispas, Advisor Bioethics, Genomic Health at the Ministry of National Education of Romania. The lecture was performed at the Training Wo...

By: Michael Beigel

Read more:
Ethical Issues & Stakeholders Attitudes Towards Code of Conduct in Nanomedicine - Video

Bankrupt biopharmas are rare. 2019 has some worried that’s changing. – BioPharma Dive

Posted on by

Editors note: This is part of a series about bankruptcy in the biopharma industry. Click here to see a running list of 2019 biopharma bankruptcies, and click here to see 31 biopharmas at high risk of bankruptcy for 2020.

Six years ago, Bind Therapeutics was flying high, with little idea how hard it would soon crash.

Headed into a public stock offering in 2013, the biotech, founded by top MIT and Harvard researchers, generated buzz with its lofty scientific ambitions. Company executives believed its nanomedicine platform, while only through Phase 1 tests, represented the next advance in cancer therapies.

Those dreams came undone within three years. As its experimental therapies struggled in clinical testing, Bind was punished by the market, and debt repayments forced the company into bankruptcy in 2016.

Bind may be a cautionary story in todays life sciences ecosystem, one that features biotechs going public at earlier stages and with heightened ambitions.

While bankruptcy is a rare outcome for biopharmas, 2019 has bucked that trend with an uptick in Chapter 11 filings. Eleven companies have declared bankruptcy so far this year, compared to an average of four per year during the past decade, according to a review of data tracked by the firm BankruptcyData.

That increase may forewarn of more companies falling to zero, industry experts said in interviews with BioPharma Dive, especially at a time of rising legal and political headwinds for the sector. After a decade of booming growth, the ballooning ranks of newly public biotechs may struggle to withstand market pressures.

I think theres a turning point now, said Andrew Hirsch, the former CEO of Bind, in an interview. I think its not sustainable.

Hirsch highlighted the rising prominence of early-stage platform companies, like Bind, going public in greater numbers and at larger valuations. That can bring steeper downside, he warned.

Things arent always going to work the first time, thats just the rule in this industry. A lot of times, companies are valued for perfection, said Hirsch, now Agios Pharmaceuticals chief financial officer.

If they are lucky and it works, thats great. But if you have a setback because youre doing novel things, the public markets can be a cruel place to be.

Biotech vastly outperformed the broader stock market over the past decade, and a steady inflow of capital supported more companies going public at rich valuations.

But those tides have turned. A leading biotech index has fallen more than 15% since peaking in the summer of last year, while the S&P 500 has ticked up nearly 13% in the same timeframe. The capital required for funding biopharmas ambitions is leaving too, with one Wall Street firm calculating $8.7 billion in net capital outflows this year rivaling a stretch in late 2015 and early 2016.

After years of outperformance, biotech has lagged the market for the past year

Price per share of a leading biotech index (XBI) and the S&P 500 (SPX) from January 2018 to October 2019 (indexed)

The base value of the index is trading value on Jan. 2, 2018.

Nami Sumida/BioPharma Dive

Investor anxiety is rising at a time when more companies are fighting for funding than in past decades. Evercore ISI analyst Josh Schimmer said this year hes noticed a marked shift in investor attitudes.

When they stumble, the markets are more unforgiving than ever, Schimmer said in an interview. They arent given second chances the way they used to be given. That may be a factor that does lead to a higher rate of bankruptcies.

And small biotechs arent the only ones facing elevated bankruptcy risk. The weight of thousands of lawsuits related to opioid marketing has already taken down Purdue Pharma and Insys Therapeutics. Several others, like Teva Pharmaceutical, Mallinckrodt and Amneal, are at risk of joining them.

The legal uncertainty has made these companies perceived as uninvestable, SVB Leerink analyst Ami Fadia said in an interview. Additionally, many of these pharmas are highly leveraged and face issues in generating cash going forward, she added.

Its pretty obvious that some of these companies are at high risk of bankruptcy, said Fadia, who covers several of these drugmakers including Mallinckrodt and Amneal.

To be sure, the effect of opioid liabilities is constrained to a comparatively small set of companies. But heading into an election year with drug pricing as a top issue, worries about capital fleeing the industry and a legal crackdown on opioid makers could be exacerbated by political threats as well.

Industry lobbyists have blasted HR3, the leading Democratic drug pricing proposal, saying it would trigger a nuclear winter by eroding the upside of biopharmas high-risk, high-reward investment premise.

If HR3 becomes law, it is lights out for a lot of very small biotech companies that are pre-revenue and depend on attracting capital, PhRMA CEO Stephen Ubl said at a recent media briefing.

Industry-specific concerns, of course, come against the backdrop of fears of a broader economic slowdown. Financial analysts have flagged recession signals in the U.S., which, if materialized, would further squeeze the industry.

It may be coming, in which capital itself is scarcer for companies, said Bob Eisenbach, a lawyer at Cooley specializing in bankruptcies. And when that happens, it puts pressure even on good companies.

Biopharmas are structured to avoid bankruptcies. Pre-revenue companies typically carry little debt and have little to restructure through a bankruptcy court if their pipeline fizzles.

Privately held biotechs that suffer clinical failures can also avoid bankruptcy by having their financial backers buy them out, saving face for those venture capitalists.

It just disappears into this great maw of the biotech universe, said Kevin Kinsella, a venture capitalist and founder of Avalon Ventures, referring to distressed biotechs in an interview.

Having launched more than 100 biopharmas, including prominent names like Vertex, Neurocrine and Onyx, Kinsella said hes been lucky enough to avoid getting entangled in any bankruptcies.

Someone absolutely failing, shutting the doors and turning off the lights, you dont really see that a lot in our industry, he said.

Drug companies, both young and old, derive value from ideas and hope more than tangible assets or resources. Just last year, early-stage platform companies like Moderna Therapeutics and Rubius Therapeutics went public with multi-billion dollar valuations despite lacking profits and significant clinical data.

But investor attitudes appear to have shifted. Rubius stock, for instance, has dropped more than 70% since its IPO. While up this month, shares in Moderna are 30% off their 52-week high in May.

Speaking generally about platform companies, Binds former CEO said market sentiment has turned.

Investors have lost their appetite for companies going public with preclinical data, Hirsch said.

Youre probably going to see more of these situations going forward, where a company is preclinical, went public and is left on their own and has to raise additional money from the public markets and they flounder.

Yet even floundering biotechs can persist for years, even decades. Long-standing industry veterans like Xoma, Novavax and Geron have survived in as-yet fruitless searches for their first drugs, suffering clinical failures along the way. Despite accumulated deficits exceeding $1 billion, these companies can find the necessary capital to keep chugging along.

Theres always someone else whos willing to bet the next discovery is around the corner, or the next asset, or if we get this clinical trial enrolled and finished, all will be good, Kinsella said. Theres always hope.

Besides selling hope, biopharmas, like all businesses, have practical options to stave off bankruptcy. Restructuring and raising cash are the main focuses, turnaround experts said.

Corporate restructurings typically shrink the business, either by laying off employees, selling assets or killing off R&D projects. Raising capital can include licensing rights to experimental therapies, taking on debt or tapping the public markets for secondary stock offerings.

If those options are exhausted, M&A can be another way out for shareholders. Firms like Deerfield Management, Hercules Capital and Highbridge Capital Management often aid distressed biotechs in such endeavours.

Deerfield, for instance, reached deals to finance R&D costs for Dynavax and helped fund Melinta Therapeutics acquisition of an infectious disease business.

A last resort can be merging with another struggling biotech, or becoming the shell in a reverse merger for another company seeking an easy path to a public listing.

Both happened in just the past few weeks. Foamix Pharmaceuticals and Menlo Therapeutics merged into one dermatology company, while NewLink Genetics was the shell through which Lumos Pharma joined public markets.

These strategies act as moats that insulate a high-risk industry from bankruptcy. In recent years, they have worked tremendously well. Among the 333 biopharmas that have gone public since 2012, just 3% filed for bankruptcy while 6% became reverse merger shells and 10% exited via M&A, according to data tracked by Evercore ISI.

But with 2019 looking shaky for biopharma, some have begun to wonder how markets will respond.

The last few years have featured record levels of capital raising, according to the investment bank Jefferies, which tallied 100 initial public offerings and 270 follow-on raises in 2018 and 2019 that drummed up tens of billions in cash.

At the same time, the number of public small and mid-sized biotechs has doubled in the past decade. There arent just more of these smaller firms; they also are worth more and consume more capital on average. From 2010 to present, these companies have seen their typical market values double, R&D budgets triple and cash burn rates quadruple, Jefferies found.

The annual burn rate for these biotechs, which includes market values from $200 million to $5 billion, has increased from $20 million to $80 million. Jefferies analyst Michael Yee credited that to free-flowing capital, more platform companies and an arms race in oncology.

Biotechs impressive market performance has made that possible. A leading biotech index, for instance, outperformed the S&P 500 by 30% since the market bottomed out in March 2009.

But of late, biotech has struggled, creating a tougher environment to raise cash.

The question is whether this is sustainable if market and macro conditions get tougher and political uncertainty gets more obvious, forcing companies to tighten their belts to ride out 2020, Yee wrote.

2019 has brought an uptick in industry bankruptcy filings

Credit: Data from Bankruptcy Data

Conditions have clearly worsened by some metrics, such as the amount of money invested in healthcare- or biotech-dedicated funds. Data tracked by a Piper Jaffray found $8.7 billion in investment has left such funds in 2019. Ten of the past 12 weeks have registered net capital outflows, a streak a Piper Jaffray analyst called seemingly the new normal.

Billions of dollars flowed out of biotech in 2015 and 2016, too, at a time when many biotech shares were falling and the prospect of a Hillary Clinton presidency had raised investor fears on drug pricing.

Biotech weathered that storm, with few companies entering bankruptcy, and has grown since. Going forward, a critical question will be gauging whether the sector is on a new trajectory or if it will emerge from this period relatively unscathed.

Getting investor attention is harder than ever to begin with, said Evercores Schimmer. For a company that has faltered, even if they are doing the right thing, its a struggle.

Read more:
Bankrupt biopharmas are rare. 2019 has some worried that's changing. - BioPharma Dive